Park Avenue Securities’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $4.21M | Sell |
73,042
-4,051
| -5% | -$233K | 0.03% | 427 |
|
|
2026
Q1 | $4.68M | Buy |
77,093
+18,508
| +32% | +$1.08M | 0.04% | 329 |
|
|
2025
Q4 | $3.16M | Buy |
58,585
+4,754
| +9% | +$229K | 0.03% | 405 |
|
|
2025
Q3 | $2.43M | Buy |
53,831
+17,266
| +47% | +$806K | 0.02% | 516 |
|
|
2025
Q2 | $1.69M | Sell |
36,565
-30,214
| -45% | -$1.48M | 0.02% | 579 |
|
|
2025
Q1 | $4.07M | Buy |
66,779
+9,973
| +18% | +$581K | 0.05% | 234 |
|
|
2024
Q4 | $3.21M | Buy |
56,806
+13,952
| +33% | +$780K | 0.03% | 334 |
|
|
2024
Q3 | $2.22M | Sell |
42,854
-1,589
| -4% | -$74.5K | 0.02% | 406 |
|
|
2024
Q2 | $1.85M | Sell |
44,443
-8,068
| -15% | -$361K | 0.02% | 437 |
|
|
2024
Q1 | $2.85M | Buy |
52,511
+12,363
| +31% | +$630K | 0.04% | 303 |
|
|
2023
Q4 | $2.06M | Sell |
40,148
-10,652
| -21% | -$559K | 0.03% | 370 |
|
|
2023
Q3 | $2.95M | Buy |
50,800
+1,063
| +2% | +$65.1K | 0.05% | 242 |
|
|
2023
Q2 | $3.18M | Sell |
49,737
-6,200
| -11% | -$416K | 0.05% | 226 |
|
|
2023
Q1 | $3.88M | Buy |
55,937
+10,343
| +23% | +$730K | 0.07% | 184 |
|
|
2022
Q4 | $3.28M | Buy |
45,594
+8,729
| +24% | +$658K | 0.06% | 202 |
|
|
2022
Q3 | $2.62M | Buy |
36,865
+2,273
| +7% | +$165K | 0.05% | 211 |
|
|
2022
Q2 | $2.66M | Buy |
34,592
+1,506
| +5% | +$115K | 0.05% | 216 |
|
|
2022
Q1 | $2.42M | Buy |
33,086
+13,078
| +65% | +$878K | 0.04% | 238 |
|
|
2021
Q4 | $1.25M | Buy |
20,008
+3,315
| +20% | +$194K | 0.02% | 386 |
|
|
2021
Q3 | $988K | Sell |
16,693
-6,468
| -28% | -$426K | 0.02% | 416 |
|
|
2021
Q2 | $1.55M | Sell |
23,161
-7,624
| -25% | -$497K | 0.03% | 272 |
|
|
2021
Q1 | $1.94M | Sell |
30,785
-3,625
| -11% | -$226K | 0.05% | 203 |
|
|
2020
Q4 | $2.13M | Buy |
34,410
+1,600
| +5% | +$98.4K | 0.06% | 148 |
|
|
2020
Q3 | $1.98M | Buy |
32,810
+2,262
| +7% | +$136K | 0.07% | 137 |
|
|
2020
Q2 | $1.8M | Buy |
+30,548
| New | +$1.83M | 0.07% | 129 |
|
|
2020
Q1 | – | Sell |
-17,666
| Closed | -$1.13M | – | 328 |
|
|
2019
Q4 | $1.13M | Buy |
17,666
+4,359
| +33% | +$250K | 0.05% | 159 |
|
|
2019
Q3 | $675K | Buy |
+13,307
| New | +$625K | 0.03% | 207 |
|
|
2019
Q2 | – | Sell |
-10,408
| Closed | -$490K | – | 276 |
|
|
2019
Q1 | $490K | Buy |
+10,408
| New | +$518K | 0.03% | 227 |
|
|
2016
Q3 | – | Sell |
-3,298
| Closed | -$243K | – | 48 |
|
|
2016
Q2 | $243K | Buy |
+3,298
| New | +$233K | 0.04% | 72 |
|
Other funds holding BMY
Park Avenue Securities's BMY Position: Q2 2026 in Review
Park Avenue Securities reduced its Bristol-Myers Squibb (BMY) stake by 5.3% in Q2 2026, selling an estimated $233K and leaving 73,042 shares worth $4.21M. The position accounts for 0.03% of the portfolio, ranked #427.
Park Avenue Securities first reported a position in BMY in Q2 2016 and has held it in 29 quarters since. The position peaked at $4.68M in Q1 2026. 2,523 funds tracked by Wall St. Rank hold BMY as of Q2 2026.
- Park Avenue Securities held 73,042 shares of Bristol-Myers Squibb worth $4.21M as of Q2 2026.
- Park Avenue Securities sold 4,051 Bristol-Myers Squibb shares in Q2 2026, an estimated $233K.
- Bristol-Myers Squibb made up 0.03% of Park Avenue Securities's portfolio in Q2 2026, its #427 holding.
- Park Avenue Securities first reported a position in Bristol-Myers Squibb in Q2 2016 and has held it in 29 quarters since.
- Park Avenue Securities's Bristol-Myers Squibb position peaked at $4.68M in Q1 2026.
- 2,523 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.
Based on Park Avenue Securities's 13F filing for Q2 2026, filed 20 Jul 2026.